Sensenonics shares are trading higher after the company announced FDA clearance for its next-generation eversense 365 continuous glucose monitoring (CGM) system for people with type 1 and type 2 diabetes aged 18 years and older.
Portfolio Pulse from Benzinga Newsdesk
Sensenonics shares rise following FDA clearance for its next-generation Eversense 365 continuous glucose monitoring system, designed for adults with type 1 and type 2 diabetes.
September 17, 2024 | 4:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sensenonics shares increased after receiving FDA clearance for its Eversense 365 CGM system, which is expected to enhance diabetes management for adults.
The FDA clearance is a significant milestone for Sensenonics, likely to boost investor confidence and drive short-term stock price gains. The new product expands their market offering, potentially increasing revenue.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100